170 related articles for article (PubMed ID: 3949846)
1. Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics.
Brock N
J Cancer Res Clin Oncol; 1986; 111(1):1-12. PubMed ID: 3949846
[TBL] [Abstract][Full Text] [Related]
2. Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture.
Brock N
Cancer Res; 1989 Jan; 49(1):1-7. PubMed ID: 2491747
[TBL] [Abstract][Full Text] [Related]
3. Basis and new developments in the field of oxazaphosphorines.
Brock N; Hilgard P; Peukert M; Pohl J; Sindermann H
Cancer Invest; 1988; 6(5):513-32. PubMed ID: 3063337
[TBL] [Abstract][Full Text] [Related]
4. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.
Brock N; Pohl J
IARC Sci Publ; 1986; (78):269-79. PubMed ID: 3108156
[TBL] [Abstract][Full Text] [Related]
5. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.
Brock N; Pohl J; Stekar J
J Cancer Res Clin Oncol; 1981; 100(3):311-20. PubMed ID: 6792207
[TBL] [Abstract][Full Text] [Related]
6. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.
Brock N; Stekar J; Pohl J; Niemeyer U; Scheffler G
Arzneimittelforschung; 1979; 29(4):659-61. PubMed ID: 114192
[TBL] [Abstract][Full Text] [Related]
7. The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.
Brock N
Recent Results Cancer Res; 1980; 74():270-8. PubMed ID: 6777836
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and transport of oxazaphosphorines and the clinical implications.
Zhang J; Tian Q; Yung Chan S; Chuen Li S; Zhou S; Duan W; Zhu YZ
Drug Metab Rev; 2005; 37(4):611-703. PubMed ID: 16393888
[TBL] [Abstract][Full Text] [Related]
9. The oxazaphosphorines.
Brock N
Cancer Treat Rev; 1983 Sep; 10 Suppl A():3-15. PubMed ID: 6627244
[No Abstract] [Full Text] [Related]
10. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
Kurowski V; Wagner T
Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
[TBL] [Abstract][Full Text] [Related]
11. Oxazaphosphorines: new therapeutic strategies for an old class of drugs.
Giraud B; Hebert G; Deroussent A; Veal GJ; Vassal G; Paci A
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):919-38. PubMed ID: 20446865
[TBL] [Abstract][Full Text] [Related]
12. [Classical oxazaphosphorines--metabolism and therapeutic properties--new implications].
Sloderbach A; Górska A; Sikorska M; Misiura K; Hładoń B
Postepy Hig Med Dosw (Online); 2013 Dec; 67():1235-53. PubMed ID: 24379264
[TBL] [Abstract][Full Text] [Related]
13. Effects of oxazaphosphorine cytostatics on granuloid progenitor cell (CFUc) proliferation in mice.
Semont H; Hecquet C; Adolphe M; Deysson G
Exp Hematol; 1982 Oct; 10(9):782-8. PubMed ID: 7173344
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide and mesna.
Schoenike SE; Dana WJ
Clin Pharm; 1990 Mar; 9(3):179-91. PubMed ID: 2107997
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy.
Chen L; Waxman DJ
Cancer Res; 1995 Feb; 55(3):581-9. PubMed ID: 7834628
[TBL] [Abstract][Full Text] [Related]
16. Trofosfamide metabolism in different species--ifosfamide is the predominant metabolite.
Boos J; Küpker F; Blaschke G; Jürgens H
Cancer Chemother Pharmacol; 1993; 33(1):71-6. PubMed ID: 8269592
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
Dechant KL; Brogden RN; Pilkington T; Faulds D
Drugs; 1991 Sep; 42(3):428-67. PubMed ID: 1720382
[TBL] [Abstract][Full Text] [Related]
18. [Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].
Burkert H; Schnitker J; Fichtner E
MMW Munch Med Wochenschr; 1979 Jun; 121(22):760-2. PubMed ID: 112422
[TBL] [Abstract][Full Text] [Related]
19. Release of a votile factor from solutions of oxazaphosphorines which damage normal and malignant cells.
Blomgren H; Hallström M
Methods Find Exp Clin Pharmacol; 1989 Jun; 11(6):391-7. PubMed ID: 2747340
[TBL] [Abstract][Full Text] [Related]
20. Mass spectrometric characterization of activated N-(2-chloroethyl)amino oxazaphosphorine derivative.
Przybylski M; Ringsdorf H; Lenssen U; Peter G; Voelcker G; Wagner T; Hohorst HJ
Biomed Mass Spectrom; 1977 Aug; 4(4):209-15. PubMed ID: 912018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]